Literature DB >> 9042105

TNF-alpha transgenic and knockout models of CNS inflammation and degeneration.

L Probert1, K Akassoglou, G Kassiotis, M Pasparakis, L Alexopoulou, G Kollias.   

Abstract

Tumour necrosis factor-alpha (TNF-alpha) plays a central role in inflammatory events including those taking place in the central nervous system (CNS), and has been implicated as a key pathogenic mediator in several human inflammatory, infectious and autoimmune CNS disorders. Using transgenic and gene knockout mice we have investigated the role of deregulated TNF-alpha production in the CNS. We show that the overexpression of wild-type murine or human TNF-alpha transgenes by resident CNS astrocytes or neurons in sufficient to trigger a neurological disorder characterised by ataxia, seizures and paresis, with histopathological features of chronic CNS inflammation and white matter degeneration. Furthermore, we show that transmembrane human TNF-alpha is sufficient to trigger CNS inflammation and degeneration when overexpressed by astrocytes but not by neurons, indicating that target cells mediating the neuroinflammatory activities of TNF-alpha localise in the vicinity of astrocytes rather than neurons. Our results establish that both soluble and transmembrane molecular forms of TNF-alpha can play critical roles in vivo in the pathogenesis of CNS inflammation and demyelination, and validate TNF-alpha transgenic and mutant mice as important models for the further study of related human CNS diseases.

Entities:  

Mesh:

Year:  1997        PMID: 9042105     DOI: 10.1016/s0165-5728(96)00184-1

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  37 in total

Review 1.  Cytokines and brain excitability.

Authors:  Michael A Galic; Kiarash Riazi; Quentin J Pittman
Journal:  Front Neuroendocrinol       Date:  2011-12-27       Impact factor: 8.606

Review 2.  Mast cells and inflammation.

Authors:  Theoharis C Theoharides; Konstantinos-Dionysios Alysandratos; Asimenia Angelidou; Danae-Anastasia Delivanis; Nikolaos Sismanopoulos; Bodi Zhang; Shahrzad Asadi; Magdalini Vasiadi; Zuyi Weng; Alexandra Miniati; Dimitrios Kalogeromitros
Journal:  Biochim Biophys Acta       Date:  2010-12-23

Review 3.  Brain inflammation as a biomarker in epilepsy.

Authors:  Annamaria Vezzani; Alon Friedman
Journal:  Biomark Med       Date:  2011-10       Impact factor: 2.851

4.  Tumor necrosis factor alpha-deficient, but not interleukin-6-deficient, mice resist peripheral infection with scrapie.

Authors:  N A Mabbott; A Williams; C F Farquhar; M Pasparakis; G Kollias; M E Bruce
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

5.  Induction and blockage of oligodendrogenesis by differently activated microglia in an animal model of multiple sclerosis.

Authors:  Oleg Butovsky; Gennady Landa; Gilad Kunis; Yaniv Ziv; Hila Avidan; Nadav Greenberg; Adi Schwartz; Igor Smirnov; Ayala Pollack; Steffen Jung; Michal Schwartz
Journal:  J Clin Invest       Date:  2006-03-23       Impact factor: 14.808

6.  Matrix Metalloproteinase-8 Inhibition Prevents Disruption of Blood-Spinal Cord Barrier and Attenuates Inflammation in Rat Model of Spinal Cord Injury.

Authors:  Hemant Kumar; Min-Jae Jo; Hyemin Choi; Manjunatha S Muttigi; Seil Shon; Byung-Joo Kim; Soo-Hong Lee; In-Bo Han
Journal:  Mol Neurobiol       Date:  2017-04-18       Impact factor: 5.590

7.  Acute treatment with minocycline, but not valproic acid, improves long-term behavioral outcomes in the Theiler's virus model of temporal lobe epilepsy.

Authors:  Melissa L Barker-Haliski; Taylor D Heck; E Jill Dahle; Fabiola Vanegas; Timothy H Pruess; Karen S Wilcox; H Steve White
Journal:  Epilepsia       Date:  2016-10-14       Impact factor: 5.864

Review 8.  Propitious Therapeutic Modulators to Prevent Blood-Spinal Cord Barrier Disruption in Spinal Cord Injury.

Authors:  Hemant Kumar; Alexander E Ropper; Soo-Hong Lee; Inbo Han
Journal:  Mol Neurobiol       Date:  2016-05-18       Impact factor: 5.590

9.  Unmasking of a protective tumor necrosis factor receptor I-mediated signal in the collagen-induced arthritis model.

Authors:  Cheryll Williams-Skipp; Thiagarajan Raman; Robert J Valuck; Herschel Watkins; Brent E Palmer; Robert I Scheinman
Journal:  Arthritis Rheum       Date:  2009-02

10.  Luteolin as a therapeutic option for multiple sclerosis.

Authors:  Theoharis C Theoharides
Journal:  J Neuroinflammation       Date:  2009-10-13       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.